Tsumura & Co (4540 JP): Q1 FY03/27 flash update
Revenue was JPY49.7bn (+15.3% YoY), with JPY41.5bn from domestic business and JPY8.2bn from China business. Operating profit was JPY7.9bn (+2.1%...
88 Views
Primer: Tsumura & Co (4540 JP) - Aug 2026
Tsumura is the dominant market leader in Japan's prescription Kampo (traditional Japanese herbal medicine) market, commanding over 80% market...
98 Views
Tsumura & Co (4540 JP): Full-year FY03/26 flash update
Revenue reached JPY192.6bn (+6.4% YoY), with domestic business at JPY161.2bn and China business at JPY31.4bn (+52.4% YoY). Operating profit was...
96 Views
Tsumura & Co (4540 JP): 1H FY03/26 flash update
Tsumura's revenue for FY03/26 is revised to JPY198.0bn, reflecting the consolidation of Shanghai Hongqiao Traditional Chinese Drug Pieces Co.,...
221 Views
Kobayashi Pharma (4967 JP): CVC/NSSK Buyout Rumour Faces an Oasis Hurdle
While the offer appears attractive relative to precedent and peer multiples, Oasis, the largest shareholder, is unlikely to back it. A higher offer...
202 Views